In humans, dominant negative PPARγ mutations are associated with obesity [121], dyslipidemia, and severe insulin resistance [122], whereas a common polymorphism (Pro12Ala) has been shown to decrease PPARγ receptor activity, improve insulin sensitivity, and decrease T2DM risk [123,124]. Here, PPARG is linked to type 2 diabetes mellitus.